RecruitingNCT06367465

Feasibility and Acceptability of HCV Treatment in Pregnancy

Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy


Sponsor

Washington University School of Medicine

Enrollment

50 participants

Start Date

Feb 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Pregnant adults over the age of 18 who are seen in the Washington University obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to BJH with hepatitis C virus infection who have a history of past or current drug use Participant Duration: Approximately 1 year. Aims: Aim 1 - Evaluate adherence and treatment completion rates when glecaprevir-pibrentasvir is started during pregnancy for women who use drugs. Aim 2 - Evaluate patient experience with hepatitis C virus treatment during pregnancy.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining whether it is feasible and acceptable to treat hepatitis C virus (HCV) infection during pregnancy in women who have a history of current or past drug use. Hepatitis C is a liver infection spread through blood contact, and this study aims to understand barriers and outcomes of treatment during pregnancy. **You may be eligible if...** - You are a woman aged 18 or older - You are currently pregnant at the time of enrollment - You have been diagnosed with active hepatitis C (HCV) infection - You have a history of past or current drug use **You may NOT be eligible if...** - There are no specific exclusion criteria listed for this study; all eligible pregnant women with HCV and a history of drug use may qualify Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGlecaprevir-pibrentasvir

Glecaprevir-pibrentasvir 100 mg / 40 mg 3 tab orally (PO) once daily for 56 days.


Locations(2)

Barnes Jewish Hospital

St Louis, Missouri, United States

Washington Univeristy

St Louis, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06367465


Related Trials